ClinConnect ClinConnect Logo
Search / Trial NCT01677026

Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache

Launched by AUTONOMIC TECHNOLOGIES, INC. · Aug 29, 2012

Trial Information

Current as of June 05, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject meets CE marked labeling for cluster headache.
  • Subject's typical cluster headache bouts last a minimum of 16 weeks, in the opinion of the Investigator.
  • Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency or dose except to manage tolerability) from Study Enrollment through the completion of the Therapy Evaluation Period.
  • Subject has the ability to read, comprehend and to reliably record information as required by the Protocol.
  • Subject is able to provide written informed consent prior to participation in the study.
  • Exclusion Criteria:
  • Subject has had a change in type, dosage or frequency of taking preventive headache medications \< one (1) month prior to Study Enrollment.
  • Per the CE marked labeling: In the opinion of the Investigator, subject has bony facial deformities, inappropriate surgical anatomy or has had facial surgery in the surgical area on the same side as the planned surgery that would prevent the proper placement of the ATI Neurostimulator.
  • Subject has other significant pain problem that might confound the study assessments in the opinion of the Investigator.

About Autonomic Technologies, Inc.

Autonomic Technologies, Inc. is a pioneering medical technology company focused on developing innovative neurostimulation therapies for the treatment of chronic pain and other neurological disorders. With a commitment to advancing patient care through cutting-edge research and development, the company leverages its expertise in neuromodulation to create minimally invasive solutions that enhance quality of life. Autonomic Technologies is dedicated to conducting rigorous clinical trials to validate the safety and efficacy of its therapies, aiming to address unmet medical needs and improve outcomes for patients suffering from debilitating conditions.

Locations

Munster, , Germany

Glostrup, , Denmark

Hamburg, , Germany

Berlin, , Germany

Bochum, , Germany

Essen, , Germany

Jena, , Germany

Kassel, , Germany

Konigstein, , Germany

Munich, , Germany

Munich, , Germany

Patients applied

0 patients applied

Trial Officials

Arne May, MD, PhD

Principal Investigator

Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials